ISSN : 2663-2187
-
Diagnostic Performance of IFAT, Blood and Lymph Node Culture and Rapid Tests in Canine Leishmaniasis and Their Association with Clinical Signs
Volume 6 | Issue - 16
-
Correlation between Frequency of Therapy Sessions and Quality of Life Index to Knee OA Grade Severity using TENS and USD
Volume 6 | Issue - 16
-
SYNTHESIS AND BIOLOGICAL EVALUATION OF SOME NEW 10- [2-SUBSTITUTEDIMINO-4-SUBSTITUTED AMINO)-1,3,5-DITHIAZINO] CHLOROPHENOTHIAZINES.
Volume 6 | Issue - 16
-
SYNTHESIS AND BIOLOGICAL EVALUATION OF SOME NEW 10- [2-SUBSTITUTEDIMINO-4-SUBSTITUTED AMINO)-1,3,5-DITHIAZINO] CHLOROPHENOTHIAZINES.
Volume 6 | Issue - 16
-
SYNTHESIS AND BIOLOGICAL EVALUATION OF SOME NEW 10- [2-SUBSTITUTEDIMINO-4-SUBSTITUTED AMINO)-1,3,5-DITHIAZINO] CHLOROPHENOTHIAZINES.
Volume 6 | Issue - 16
Management of lower urinary tract symptoms during intravesical BCG therapy
Main Article Content
Abstract
Intravesical immunotherapy with Bacillus Calmette-Guerin (BCG) is commonly used as an adjuvant treatment following transurethral resection of high-risk non-muscle invasive bladder cancer (NMIBC). The completion of treatment maintenance schedules can often require a maximum of three years. Patients successfully complete the entire 3-year BCG maintenance, experience significant advantages, including a 27% decrease progression and a 32% reduction in recurrence risk as compared to intravesical treatment with mitomycin.[1]
